Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Post-ASCO & EHA 2024 MPN Highlights

25 June 2024 | Virtual Meeting

Presentation summaries of key MPN abstracts from ASCO & EHA 2024 featuring panel discussions with leading experts

The Post-ASCO & EHA 2024 MPN Highlights was supported by GSK. Supporters have no influence over the production of content.

Novel treatments and treatment combinations for MPNs Updates in outcomes following HSCT in myelofibrosis Current evidence for long-term & real-world outcomes

Novel treatments and treatment combinations for MPNs

Jean-Jacques Kiladjian

JAK2V617F molecular response correlates with EFS in an early PV population

Jean-Jacques Kiladjian Saint-Louis Hospital & Paris Diderot University, Paris, France

Claire Harrison

RESTORE: Elritercept for MF and mitigating ruxolitinib-associated cytopenias

Claire Harrison Guy’s and St. Thomas’ NHS Foundation Trust, London, United Kingdom

Raajit Rampal

MANIFEST-2: pelabresib + ruxolitinib for JAKi treatment-naïve pts with MF

Raajit Rampal Memorial Sloan Kettering Cancer Center, New York City, NY, United States

Naveen Pemmaraju

TRANSFORM-1: navitoclax + RUX vs. RUX + PBO in pts with untreated MF

Naveen Pemmaraju The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Alex Rampotas

A novel CAR-T cell therapy against calreticulin mutant neoplasms

Alex Rampotas University College London Cancer Institute, London, United Kingdom

Session 1 panel discussion

Updates in outcomes following HSCT in myelofibrosis

Kristin Rathje

Comparing pre-tranplant, peri-transplant and no JAKi on outcomes after HSCT for MF

Kristin Rathje University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Haris Ali

Hypomethylating agents are effective in treating relapsed MF post allo-HSCT

Haris Ali City of Hope, Duarte, CA, United States

Session 2 panel discussion

Current evidence for long-term & real-world outcomes

Nieves Garcia-Gisbert

Clinical & molecular characterisation of pts w. low JAK2V617F allele burden

Nieves Garcia-Gisbert Hospital del Mar Research Institute, Barcelona, Spain

Valentin Garcia Gutiérrez

Momelotinib as an alternative therapy to other JAKi in MF pts with anemia

Valentin Garcia Gutiérrez Ramón y Cajal Hospital, Madrid, Spain

John Mascarenhas

RW treatment patterns & outcomes in pts w. MF treated w. pacritinib in USA

John Mascarenhas Icahn School of Medicine at Mount Sinai, New York City, NY, United States

Session 3 panel discussion

Supported by:

Gold Supporters